Jump to content

Hippo signaling pathway

From Wikipedia, the free encyclopedia
(Redirected from Hippo pathway)

MST1, the human homologue of the Hippo protein, is part of the Hippo signalling pathway in humans

The Hippo signaling pathway, also known as the Salvador-Warts-Hippo (SWH) pathway, is a signaling pathway that controls organ size in animals through the regulation of cell proliferation and apoptosis. The pathway takes its name from one of its key signaling components—the protein kinase Hippo (Hpo). Mutations in this gene lead to tissue overgrowth, or a "hippopotamus"-like phenotype.

A fundamental question in developmental biology is how an organ knows to stop growing after reaching a particular size. Organ growth relies on several processes occurring at the cellular level, including cell division and programmed cell death (or apoptosis). The Hippo signaling pathway is involved in restraining cell proliferation and promoting apoptosis. As many cancers are marked by unchecked cell division, this signaling pathway has become increasingly significant in the study of human cancer.[1] The Hippo pathway also has a critical role in stem cell and tissue specific progenitor cell self-renewal and expansion.[2]

The Hippo signaling pathway appears to be highly conserved. While most of the Hippo pathway components were identified in the fruit fly (Drosophila melanogaster) using mosaic genetic screens, orthologs to these components (genes that are related through speciation events and thus tend to retain the same function in different species) have subsequently been found in mammals. Thus, the delineation of the pathway in Drosophila has helped to identify many genes that function as oncogenes or tumor suppressors in mammals.

Mechanism

[edit]

The Hippo pathway consists of a core kinase cascade in which Hpo phosphorylates (Drosophila) the protein kinase Warts (Wts).[3][4] Hpo (MST1/2 in mammals) is a member of the Ste-20 family of protein kinases. This highly conserved group of serine/threonine kinases regulates several cellular processes, including cell proliferation, apoptosis, and various stress responses.[5] Once phosphorylated, Wts (LATS1/2 in mammals) becomes active. Misshapen (Msn, MAP4K4/6/7 in mammals) and Happyhour (Hppy, MAP4K1/2/3/5 in mammals) act in parallel to Hpo to activate Wts.[6][7][8] Wts is a nuclear DBF-2-related kinase. These kinases are known regulators of cell cycle progression, growth, and development.[9] Two proteins are known to facilitate the activation of Wts: Salvador (Sav) and Mob as tumor suppressor (Mats). Sav (SAV1 in mammals) is a WW domain-containing protein, meaning that this protein contains a sequence of amino acids in which a tryptophan and an invariant proline are highly conserved.[10] Hpo can bind to and phosphorylate Sav, which may function as a scaffold protein because this Hpo-Sav interaction promotes phosphorylation of Wts.[11] Hpo can also phosphorylate and activate Mats (MOBKL1A/B in mammals), which allows Mats to associate with and strengthen the kinase activity of Wts.[12]

Activated Wts can then go on to phosphorylate and inactivate the transcriptional coactivator Yorkie (Yki). Yki is unable to bind DNA by itself. In its active state, Yki binds to the transcription factor Scalloped (Sd), and the Yki-Sd complex becomes localized to the nucleus. This allows for the expression of several genes that promote organ growth, such as cyclin E, which promotes cell cycle progression, and diap1 (Drosophila inhibitor of apoptosis protein-1), which, as its name suggests, prevents apoptosis.[13] Yki also activates expression of the bantam microRNA, a positive growth regulator that specifically affects cell number.[14][15] Thus, the inactivation of Yki by Wts inhibits growth through the transcriptional repression of these pro-growth regulators. By phosphorylating Yki at serine 168, Wts promotes the association of Yki with 14-3-3 proteins, which help to anchor Yki in the cytoplasm and prevent its transport to the nucleus. In mammals, the two Yki orthologs are Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (WWTR1, also known as TAZ).[16] When activated, YAP and TAZ can bind to several transcription factors including p73, Runx2 and several TEADs.[17] YAP regulates the expression of Hoxa1 and Hoxc13 in mouse and human epithelial cells in vivo and in vitro.[18]

The upstream regulators of the core Hpo/Wts kinase cascade include the transmembrane protein Fat and several membrane-associated proteins. As an atypical cadherin, Fat (FAT1-4 in mammals) may function as a receptor, though an extracellular ligand has not been positively identified. The GPI-anchored cell surface protein glypican-3 (GPC3) is known to interact with Fat1 in human liver cancer.[19] GPC3 is also shown to modulate Yap signaling in liver cancer.[20] While Fat is known to bind to another atypical cadherin, Dachsous (Ds), during tissue patterning,[21] it is unclear what role Ds has in regulating tissue growth. Nevertheless, Fat is recognized as an upstream regulator of the Hpo pathway. Fat activates Hpo through the apical protein Expanded (Ex; FRMD6/Willin in mammals). Ex interacts with two other apically-localized proteins, Kibra (KIBRA in mammals) and Merlin (Mer; NF2 in mammals), to form the Kibra-Ex-Mer (KEM) complex. Both Ex and Mer are FERM domain-containing proteins, while Kibra, like Sav, is a WW domain-containing protein.[22] The KEM complex physically interacts with the Hpo kinase cascade, thereby localizing the core kinase cascade to the plasma membrane for activation.[23] Fat may also regulate Wts independently of Ex/Hpo, through the inhibition of the unconventional myosin Dachs. Normally, Dachs can bind to and promote the degradation of Wts.[24]

In cancer

[edit]

In fruitfly, the Hippo signaling pathway involves a kinase cascade involving the Salvador (Sav), Warts (Wts) and Hippo (Hpo) protein kinases.[25] Many of the genes involved in the Hippo signaling pathway are recognized as tumor suppressors, while Yki/YAP/TAZ is identified as an oncogene. YAP/TAZ can reprogram cancer cells into cancer stem cells.[26] YAP has been found to be elevated in some human cancers, including breast cancer, colorectal cancer, and liver cancer.[27][28][29] This may be explained by YAP’s recently defined role in overcoming contact inhibition, a fundamental growth control property of normal cells in vitro and in vivo, in which proliferation stops after cells reach confluence[30] (in culture) or occupy maximum available space inside the body and touch one another. This property is typically lost in cancerous cells, allowing them to proliferate in an uncontrolled manner.[31] In fact, YAP overexpression antagonizes contact inhibition.[32]

Many of the pathway components recognized as tumor suppressor genes are mutated in human cancers. For example, mutations in Fat4 have been found in breast cancer,[33] while NF2 is mutated in familial and sporadic schwannomas.[34] Additionally, several human cancer cell lines invoke mutations of the SAV1 and MOBK1B proteins.[35][36] However, recent research by Marc Kirschner and Taran Gujral has demonstrated that Hippo pathway components may play a more nuanced role in cancer than previously thought. Hippo pathway inactivation enhanced the effect of 15 FDA-approved oncology drugs by promoting chemo-retention.[37] In another study, the Hippo pathway kinases LATS1/2 were found to suppress cancer immunity in mice.[38] Not all studies, however, support a role for Hippo signaling in promoting carcinogenesis. In hepatocellular carcinoma, for instance, it was suggesting that AXIN1 mutations would provoke Hippo signaling pathway activation, fostering the cancer development, but a recent study demonstrated that such an effect cannot be detected.[39] Thus the exact role of Hippo signaling in the cancer process awaits further elucidation.

As a drug target

[edit]

Two venture-backed oncology startups, Vivace Therapeutics and the General Biotechnologies subsidiary Nivien Therapeutics, are actively developing kinase inhibitors targeting the Hippo pathway.[40]

Regulation of human organ size

[edit]

The heart is the first organ formed during mammalian development. A properly sized and functional heart is vital throughout the entire lifespan. Loss of cardiomyocytes because of injury or diseases leads to heart failure, which is a major cause of human morbidity and mortality. Unfortunately, regenerative potential of the adult heart is limited. The Hippo pathway is a recently identified signaling cascade that plays an evolutionarily conserved role in organ size control by inhibiting cell proliferation, promoting apoptosis, regulating fates of stem/progenitor cells, and in some circumstances, limiting cell size. Research indicates a key role of this pathway in regulation of cardiomyocyte proliferation and heart size. Inactivation of the Hippo pathway or activation of its downstream effector, the Yes-associated protein transcription coactivator, improves cardiac regeneration. Several known upstream signals of the Hippo pathway such as mechanical stress, G-protein-coupled receptor signaling, and oxidative stress are known to play critical roles in cardiac physiology. In addition, Yes-associated protein has been shown to regulate cardiomyocyte fate through multiple transcriptional mechanisms.[41][42][43]

Gene name confusion

[edit]

Note that Hippo TAZ protein is often confused with the gene TAZ, which is unrelated to the Hippo pathway. The gene TAZ produces the protein tafazzin. The official gene name for the Hippo TAZ protein is WWTR1. Also, the official names for MST1 and MST2 are STK4 and STK3, respectively. All databases for bioinformatics use the official gene symbols, and commercial sources for PCR primers or siRNA also go by the official gene names.

Summary table

[edit]
Drosophila melanogaster Human ortholog(s) Protein description and role in Hippo signaling pathway
Dachsous (Ds) DCHS1, DCHS2 Atypical cadherin that may act as a ligand for the Fat receptor
Fat (Ft) FAT1, FAT2, FAT3, FAT4 Atypical cadherin that may act as a receptor for the Hippo pathway
Expanded (Ex) FRMD6 FERM domain-containing apical protein that associates with Kibra and Mer as an upstream regulator of the core kinase cascade
Dachs (Dachs) Unconventional myosin that can bind Wts, promoting its degradation
Kibra (Kibra) WWC1 WW domain-containing apical protein that associates with Ex and Mer as an upstream regulator of the core kinase cascade
Merlin (Mer) NF2 FERM domain-containing apical protein that associates with Ex and Kibra as an upstream regulator of the core kinase cascade
Hippo (Hpo) MST1, MST2 – officially STK4/3 Sterile-20-type kinase that phosphorylates and activates Wts
Salvador (Sav) SAV1 WW domain-containing protein that may act as a scaffold protein, facilitating Warts phosphorylation by Hippo
Warts (Wts) LATS1, LATS2 Nuclear DBF-2-related kinase that phosphorylates and inactivates Yki
Mob as tumor suppressor (Mats) MOBKL1A, MOBKL1B Kinase that associates with Wts to potentiate its catalytic activity
Yorkie (Yki) YAP, TAZ – officially WWTR1 Transcriptional coactivator that binds to Sd in its active, unphosphorylated form to activate expression of transcriptional targets that promote cell growth, cell proliferation, and prevent apoptosis
Scalloped (Sd) TEAD1, TEAD2, TEAD3, TEAD4 Transcription factor that binds Yki to regulate target gene expression

References

[edit]
  1. ^ Saucedo LJ, Edgar BA (August 2007). "Filling out the Hippo pathway". Nature Reviews. Molecular Cell Biology. 8 (8): 613–21. doi:10.1038/nrm2221. PMID 17622252. S2CID 34712807.
  2. ^ Zhao B, Tumaneng K, Guan KL (August 2011). "The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal". Nature Cell Biology. 13 (8): 877–83. doi:10.1038/ncb2303. PMC 3987945. PMID 21808241.
  3. ^ Pan D (October 2010). "The hippo signaling pathway in development and cancer". Developmental Cell. 19 (4): 491–505. doi:10.1016/j.devcel.2010.09.011. PMC 3124840. PMID 20951342.
  4. ^ Meng Z, Moroishi T, Guan KL (January 2016). "Mechanisms of Hippo pathway regulation". Genes & Development. 30 (1): 1–17. doi:10.1101/gad.274027.115. PMC 4701972. PMID 26728553.
  5. ^ Dan I, Watanabe NM, Kusumi A (May 2001). "The Ste20 group kinases as regulators of MAP kinase cascades". Trends in Cell Biology. 11 (5): 220–30. doi:10.1016/S0962-8924(01)01980-8. PMID 11316611.
  6. ^ Meng Z, Moroishi T, Mottier-Pavie V, Plouffe SW, Hansen CG, Hong AW, et al. (October 2015). "MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway". Nature Communications. 6: 8357. Bibcode:2015NatCo...6.8357M. doi:10.1038/ncomms9357. PMC 4600732. PMID 26437443.
  7. ^ Zheng Y, Wang W, Liu B, Deng H, Uster E, Pan D (September 2015). "Identification of Happyhour/MAP4K as Alternative Hpo/Mst-like Kinases in the Hippo Kinase Cascade". Developmental Cell. 34 (6): 642–55. doi:10.1016/j.devcel.2015.08.014. PMC 4589524. PMID 26364751.
  8. ^ Li Q, Li S, Mana-Capelli S, Roth Flach RJ, Danai LV, Amcheslavsky A, et al. (November 2014). "The conserved misshapen-warts-Yorkie pathway acts in enteroblasts to regulate intestinal stem cells in Drosophila". Developmental Cell. 31 (3): 291–304. doi:10.1016/j.devcel.2014.09.012. PMC 4254555. PMID 25453828.
  9. ^ Ma J, Benz C, Grimaldi R, Stockdale C, Wyatt P, Frearson J, et al. (May 2010). "Nuclear DBF-2-related kinases are essential regulators of cytokinesis in bloodstream stage Trypanosoma brucei". The Journal of Biological Chemistry. 285 (20): 15356–68. doi:10.1074/jbc.M109.074591. PMC 2865264. PMID 20231285.
  10. ^ André B, Springael JY (December 1994). "WWP, a new amino acid motif present in single or multiple copies in various proteins including dystrophin and the SH3-binding Yes-associated protein YAP65". Biochemical and Biophysical Research Communications. 205 (2): 1201–5. doi:10.1006/bbrc.1994.2793. PMID 7802651.
  11. ^ Wu S, Huang J, Dong J, Pan D (August 2003). "hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts". Cell. 114 (4): 445–56. doi:10.1016/S0092-8674(03)00549-X. PMID 12941273. S2CID 9532050.
  12. ^ Wei X, Shimizu T, Lai ZC (April 2007). "Mob as tumor suppressor is activated by Hippo kinase for growth inhibition in Drosophila". The EMBO Journal. 26 (7): 1772–81. doi:10.1038/sj.emboj.7601630. PMC 1847660. PMID 17347649.
  13. ^ Huang J, Wu S, Barrera J, Matthews K, Pan D (August 2005). "The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP". Cell. 122 (3): 421–34. doi:10.1016/j.cell.2005.06.007. PMID 16096061. S2CID 14139806.
  14. ^ Thompson BJ, Cohen SM (August 2006). "The Hippo pathway regulates the bantam microRNA to control cell proliferation and apoptosis in Drosophila". Cell. 126 (4): 767–74. doi:10.1016/j.cell.2006.07.013. PMID 16923395. S2CID 15264514.
  15. ^ Nolo R, Morrison CM, Tao C, Zhang X, Halder G (October 2006). "The bantam microRNA is a target of the hippo tumor-suppressor pathway". Current Biology. 16 (19): 1895–904. Bibcode:2006CBio...16.1895N. doi:10.1016/j.cub.2006.08.057. PMID 16949821. S2CID 15742844.
  16. ^ Wang K, Degerny C, Xu M, Yang XJ (February 2009). "YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human disease". Biochemistry and Cell Biology. 87 (1): 77–91. doi:10.1139/O08-114. PMID 19234525.
  17. ^ Badouel C, Garg A, McNeill H (December 2009). "Herding Hippos: regulating growth in flies and man". Current Opinion in Cell Biology. 21 (6): 837–43. doi:10.1016/j.ceb.2009.09.010. PMID 19846288.
  18. ^ Liu M, Zhao S, Lin Q, Wang XP (April 2015). "YAP regulates the expression of Hoxa1 and Hoxc13 in mouse and human oral and skin epithelial tissues". Molecular and Cellular Biology. 35 (8): 1449–61. doi:10.1128/MCB.00765-14. PMC 4372702. PMID 25691658.
  19. ^ Meng P, Zhang YF, Zhang W, Chen X, Xu T, Hu S, et al. (January 2021). "Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells". Scientific Reports. 11 (1): 40. doi:10.1038/s41598-020-79524-3. PMC 7794441. PMID 33420124.
  20. ^ Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, et al. (March 2013). "Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma". Proceedings of the National Academy of Sciences of the United States of America. 110 (12): E1083 – E1091. Bibcode:2013PNAS..110E1083F. doi:10.1073/pnas.1217868110. PMC 3607002. PMID 23471984.
  21. ^ Cho E, Irvine KD (September 2004). "Action of fat, four-jointed, dachsous and dachs in distal-to-proximal wing signaling". Development. 131 (18): 4489–500. doi:10.1242/dev.01315. PMID 15342474.
  22. ^ Baumgartner R, Poernbacher I, Buser N, Hafen E, Stocker H (February 2010). "The WW domain protein Kibra acts upstream of Hippo in Drosophila". Developmental Cell. 18 (2): 309–16. doi:10.1016/j.devcel.2009.12.013. PMID 20159600.
  23. ^ Pan D (October 2010). "The hippo signaling pathway in development and cancer". Developmental Cell. 19 (4): 491–505. doi:10.1016/j.devcel.2010.09.011. PMC 3124840. PMID 20951342.
  24. ^ Cho E, Feng Y, Rauskolb C, Maitra S, Fehon R, Irvine KD (October 2006). "Delineation of a Fat tumor suppressor pathway". Nature Genetics. 38 (10): 1142–50. doi:10.1038/ng1887. PMID 16980976. S2CID 25818643.
  25. ^ "Yki - Transcriptional coactivator yorkie - Drosophila melanogaster (Fruit fly) - yki gene & protein".
  26. ^ Piccolo S, Dupont S, Cordenonsi M (October 2014). "The biology of YAP/TAZ: hippo signaling and beyond". Physiological Reviews. 94 (4): 1287–312. doi:10.1152/physrev.00005.2014. PMID 25287865.
  27. ^ Kango-Singh M, Singh A (July 2009). "Regulation of organ size: insights from the Drosophila Hippo signaling pathway". Developmental Dynamics. 238 (7): 1627–37. doi:10.1002/dvdy.21996. PMID 19517570. S2CID 1853119.
  28. ^ Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. (June 2006). "Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach". Cell. 125 (7): 1253–67. doi:10.1016/j.cell.2006.05.030. PMC 3026384. PMID 16814713.
  29. ^ Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, et al. (November 2008). "Expression of Yes-associated protein in common solid tumors". Human Pathology. 39 (11): 1582–9. doi:10.1016/j.humpath.2008.04.012. PMC 2720436. PMID 18703216.
  30. ^ Eagle H, Levine EM (March 1967). "Growth regulatory effects of cellular interaction". Nature. 213 (5081): 1102–6. Bibcode:1967Natur.213.1102E. doi:10.1038/2131102a0. PMID 6029791. S2CID 4256818.
  31. ^ Hanahan D, Weinberg RA (January 2000). "The hallmarks of cancer". Cell. 100 (1): 57–70. doi:10.1016/S0092-8674(00)81683-9. PMID 10647931. S2CID 1478778.
  32. ^ Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. (November 2007). "Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control". Genes & Development. 21 (21): 2747–61. doi:10.1101/gad.1602907. PMC 2045129. PMID 17974916.
  33. ^ Qi C, Zhu YT, Hu L, Zhu YJ (February 2009). "Identification of Fat4 as a candidate tumor suppressor gene in breast cancers". International Journal of Cancer. 124 (4): 793–8. doi:10.1002/ijc.23775. PMC 2667156. PMID 19048595.
  34. ^ Evans DG, Sainio M, Baser ME (December 2000). "Neurofibromatosis type 2". Journal of Medical Genetics. 37 (12): 897–904. doi:10.1136/jmg.37.12.897. PMC 1734496. PMID 11106352.
  35. ^ Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber D, et al. (August 2002). "salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines". Cell. 110 (4): 467–78. doi:10.1016/S0092-8674(02)00824-3. PMID 12202036. S2CID 18204088.
  36. ^ Lai ZC, Wei X, Shimizu T, Ramos E, Rohrbaugh M, Nikolaidis N, et al. (March 2005). "Control of cell proliferation and apoptosis by mob as tumor suppressor, mats". Cell. 120 (5): 675–85. doi:10.1016/j.cell.2004.12.036. PMID 15766530. S2CID 13785447.
  37. ^ Gujral TS, Kirschner MW (May 2017). "Hippo pathway mediates resistance to cytotoxic drugs". Proceedings of the National Academy of Sciences of the United States of America. 114 (18): E3729 – E3738. Bibcode:2017PNAS..114E3729G. doi:10.1073/pnas.1703096114. PMC 5422801. PMID 28416665.
  38. ^ Moroishi T, Hayashi T, Pan WW, Fujita Y, Holt MV, Qin J, et al. (December 2016). "The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity". Cell. 167 (6): 1525–1539.e17. doi:10.1016/j.cell.2016.11.005. PMC 5512418. PMID 27912060.
  39. ^ Zhang R, Li S, Schippers K, Eimers B, Niu J, Hornung BV, et al. (June 2024). "Unraveling the impact of AXIN1 mutations on HCC development: Insights from CRISPR/Cas9 repaired AXIN1-mutant liver cancer cell lines". PLOS ONE. 19 (6): e0304607. doi:10.1371/journal.pone.0304607. PMC 11161089. PMID 38848383.
  40. ^ "Vivace uncloaks with $40M, U.S.-China backing for cancer trials". FierceBiotech. 28 June 2017. Retrieved 2017-11-04.
  41. ^ Qin F, Tian J, Zhou D, Chen L (August 2013). "Mst1 and Mst2 kinases: regulations and diseases". Cell & Bioscience. 3 (1): 31. doi:10.1186/2045-3701-3-31. PMC 3849747. PMID 23985272.
  42. ^ Hilman D, Gat U (August 2011). "The evolutionary history of YAP and the hippo/YAP pathway". Molecular Biology and Evolution. 28 (8): 2403–17. doi:10.1093/molbev/msr065. PMID 21415026.
  43. ^ Boopathy GT, Hong W (2019). "Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis". Frontiers in Cell and Developmental Biology. 7: 49. doi:10.3389/fcell.2019.00049. ISSN 2296-634X. PMC 6468149. PMID 31024911.

Further reading

[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hippo_signaling_pathway&oldid=1250453826"